scholarly journals Modern Approaches to Vaccinal Prevention of a Pneumococcal Infection in Adults Patients with Diabetes Mellitus (Literature Review)

2018 ◽  
Vol 17 (2) ◽  
pp. 83-90
Author(s):  
J. A. Paramonova ◽  
L. B. Postnikova ◽  
M. P. Kostinov ◽  
A. A. Tarasova ◽  
V. A. Pogrebetzkaya
Keyword(s):  
Diabetes Mellitus ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Pneumococcal Infection ◽  
Cost Effective ◽  
Morbidity Rate ◽  
Pneumococcal Infections ◽  
Increased Risk ◽  
Patients With Diabetes

At present, pneumococcal infections remain a major cause of morbidity and mortality around the world, being one of the ten leading causes of death worldwide. Some medical conditions, like  diabetes mellitus (DM) are associated with an increased risk of  pneumococcal infections and vaccination was calculated to be highly  cost-effective among those adults with an increased risk. The article  analyzes world data on pneumococcal infection morbidity rate among diabetes mellitus patients and possible ways of reducing it through  immunization. In December 2011, the Food and Drug Administration  (FDA) licensed 13-valent pneumococcal conjugate vaccine (PCV13)  for prevention of pneumonia and invasive pneumococcal disease in  adults aged ≥ 50 years. However, the efficacy of PCV in individuals  with specific comorbidities is yet unknown. The article presents the  findings of research which investigated the efficacy of  antipneumococcal vaccination among diabetes mellitus patients. It  also gives data of first-hand experience of 13-valent pneumococcal conjugate vaccine use (Prevenar 13, Pfizer).

scholarly journals Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

2005 ◽  
Vol 12 (1) ◽  
pp. 218-223 ◽  
Author(s):  
Daniel J. Sikkema ◽  
Nancy A. Ziembiec ◽  
Thomas R. Jones ◽  
Stephen W. Hildreth ◽  
Dace V. Madore ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Immune Responses ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Pneumococcal Infection ◽  
Capsular Polysaccharides ◽  
Standardization Method ◽  
Igg2 Antibody ◽  
Reference Serum

ABSTRACT Weight-based assignments for immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to Streptococcus pneumoniae capsular polysaccharides (PnPs) in antipneumococcal standard reference serum lot 89-S (lot 89-S), also known as lot 89-SF, have been determined for serotypes 1, 4, 5, 7F, 9V, and 18C. This extends the usefulness of lot 89-S beyond the IgG1 and IgG2 subclass assignments for serotypes 3, 6B, 14, 19F, and 23F made previously (A. Soininen, H. Kayhty, I. Seppala, and T. Wuorimaa, Clin. Diagn. Lab. Immunol. 5:561-566, 1998) to cover 11 major serotypes associated with the highest percentage of pneumococcal disease worldwide. A method of equivalence of absorbances in enzyme immunosorbent assays was used to determine the IgG1 and IgG2 antibody concentrations for the additional serotypes in lot 89-S, based on the subclass values previously assigned for PnPs serotypes 6B, 14, and 23F. This cross-standardization method assures consistency with previous antibody assignments in that reference serum. The newly assigned subclass values for serotype 9V, and previously assigned values for serotype 14, were used to quantitate PnPs antibodies in sera from adult and pediatric subjects immunized with a pneumococcal conjugate vaccine. There was a predominance of IgG1 anti-PnPs antibodies in pediatric sera and IgG2 anti-PnPs antibodies in the adult sera. The IgG1 and IgG2 subclass assignments for the 11 PnPs serotypes in antipneumococcal standard reference serum lot 89-S are useful for quantitating and characterizing immune responses to pneumococcal infection and vaccination regimens.

Prevention ofStreptococcus pneumoniae(pneumococcal) infections in adults

2014 ◽  
Vol 155 (50) ◽  
pp. 1996-2004 ◽  
Author(s):  
Endre Ludwig ◽  
Zsófia Mészner
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Infection ◽  
Polysaccharide Vaccine ◽  
Diagnostic Tools ◽  
Renal Diseases ◽  
Pneumococcal Polysaccharide Vaccine ◽  
Pneumococcal Infections ◽  
Incidence And Mortality ◽  
One Year

Infections caused by Streptococcus pneumoniae (pneumococcus) are still meaning a serious health problem, about 40% of community acquired pneumonia (CAP) is due to pneumococcal bacteria in adults requiring hospitalization. The incidence and mortality rate of pneumococcal infections is increasing in the population above 50 years of age. Certain congenital and acquired immunocompromised conditions make the individual susceptible for pneumococcal infection and other chronic comorbidities should be considered as a risk factor as well, such as liver and renal diseases, COPD, diabetes mellitus. Lethality of severe pneumococcal infections with bacteraemia still remains about 12% despite adequate antimicrobial therapy in the past 60 years. Underestimation of pneumococcal infections is mainly due to the low sensitivity of diagnostic tools and underuse of bacteriological laboratory confirmation methods. 13-valent pneumococcal conjugate vaccine (PCV-13) became available recently beyond the 23-valent polysacharide vaccine (PPV-23) which has been using for a long time.The indication and proper administration of the two vaccines are based on international recommendations and vaccination guideline published by National Centre for Epidemiology (NCE):Pneumococcal vaccination is recommended for: Every person above 50 years of age. Patients of all ages with chronic diseases who are susceptible for severe pneumococcal infections: respiratory (COPD), heart, renal, liver disease, diabetes, or patients under immunsuppressive treatment. Smokers regardless of age and comorbidities. Cochlear implants, cranial-injured patients. Patients with asplenia.Recommendation for administration of the two different vaccines:Adults who have not been immunized previously against pneumococcal disease must be vaccinated with a dose of 13-valent pneumococcal conjugate vaccine first. This protection could be extended with administration of 23-valent pneumococcal polysaccharide vaccine at least two month later. Adults who have been immunized previously, but above 65 years of age, with a 23-valent polysaccharide vaccine are recommended to get one dose of conjugate vaccine at least one year later. Adults who have been immunized previously, but under 65 years of age, with a 23-valent polysaccharide vaccine are recommended to get one dose of conjugate vaccine at least one year later. After a minimal interval of two months one dose of 23-valent pneumococcal polysaccharide vaccine is recommended if at least 5 years have elapsed since their previous PPSV23 dose. Vaccination of immuncompromised patients (malignancy, transplantation, etc.) and patients with asplenia should be defined by vaccinology specialists. Pneumococcal vaccines may be administered concommitantly or any interval with other vaccines. Orv. Hetil., 2014, 155(50), 1996–2004.

scholarly journals Changes in invasive pneumococcal disease among adults living with HIV following introduction of 13-valent pneumococcal conjugate vaccine, 2008–2014

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S57-S58
Author(s):  
Miwako Kobayashi ◽  
William Adih ◽  
Jianmin Li ◽  
Ryan Gierke ◽  
Olivia M Almendares ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Indirect Effects ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Census Data ◽  
People Living With Hiv ◽  
Childhood Immunization ◽  
Increased Risk ◽  
Living With Hiv

Abstract Background People living with HIV (PLHIV) are at increased risk of invasive pneumococcal disease (IPD). Introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in children in 2010 reduced adult IPD burden (indirect effects). In 2012, PCV13 was recommended in series with 23-valent polysaccharide vaccine (PPSV23) for adults with immunocompromising conditions, including PLHIV. We evaluated changes in IPD incidence in adults ≥19 years old with and without HIV after PCV13 introduction for children in 2010 and for immunocompromised adults in 2012. PCV13 coverage for adults 19–64 years old with indications was 6% in 2014. Methods IPD cases, defined as pneumococcal isolation from sterile sites, were identified through CDC’s Active Bacterial Core surveillance, with counts projected nationally. HIV status was obtained from medical records. Isolates were serotyped by Quellung reaction or PCR and grouped into PCV13-types, PPV11-types (unique to PPSV23), or non-vaccine types. We estimated IPD incidence (cases per 100,000 people) using national case-based HIV surveillance (for PLHIV) or US Census data (for non-PLHIV) as denominators. We compared IPD incidence in 2011–12 and 2013–14 to the pre-PCV13 baseline (2008–09) by serotype groups. Results Overall IPD incidence at baseline was 354.0 for PLHIV and 15.5 for non-PLHIV. From baseline to 2013–14, IPD rates declined in both PLHIV (-36.3%; 95% CI: -38.8, -33.7%) and non-PLHIV (-27.3%; 95% CI: -28.2, -26.5%). The largest reductions were noted in PCV13-type IPD in both PLHIV (Figure 1) and non-PLHIV (Figure 2) for both periods (-46.8% for PLHIV and -45.9% for non-PLHIV in 2011–12; -60.3% for PLHIV and -65.8% for non-PLHIV in 2013–14). Overall IPD rates were 22.8 (95% CI: 22.2, 23.4) times as high in PLHIV compared with non-PLHIV at baseline, and 19.4 (95% CI: 18.8, 20.0) times as high in 2013–2014. Conclusion IPD rates declined significantly in both PLHIV and non-PLHIV during the study period due to reductions in PCV13-type IPD; however, IPD rates remained 20-fold in PLHIV compared with non-PLHIV. Similar magnitude reductions in PCV13-type IPD in both groups and low PCV13 coverage in immunocompromised adults suggest that most of the observed decline is due to PCV13 indirect effects from childhood immunization. Disclosures L. Harrison, GSK: Scientific Advisor, Consulting fee; W. Schaffner, Pfizer: Scientific Advisor, Consulting fee; Merck: Scientific Advisor, Consulting fee; Novavax: Consultant, Consulting fee; Dynavax: Consultant, Consulting fee; Sanofi-pasteur: Consultant, Consulting fee; GSK: Consultant, Consulting fee; Seqirus: Consultant, Consulting fee

scholarly journals The epidemiology of pneumococcal infection in children in the developing world

1999 ◽  
Vol 354 (1384) ◽  
pp. 777-785 ◽  
Author(s):  
Brian Greenwood
Keyword(s):  
Young Children ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Disease ◽  
Developing World ◽  
Pneumococcal Infection ◽  
Field Trials ◽  
Industrialized Countries ◽  
Pneumococcal Infections ◽  
Increased Risk ◽  
Meningitis In Children

Pneumonia causes about three million deaths a year in young children, nearly all of which are in developing countries. Streptococcus pneumoniae (the pneumococcus) is the most important bacterial cause of pneumonia in young children and so is likely to be responsible for a high proportion of these deaths. The pneumococcus is also responsible for a substantial proportion of the 100 000–500 000 deaths that occur from meningitis in children each year. The incidence of invasive pneumococcal disease in children in the developing world is several times higher than in industrialized countries. This discrepancy may, in part, be due to socio–economic differences but genetic factors may also play a role. Children with sickle cell disease have a substantially increased risk of invasive pneumococcal infection and a search is being made for other possible genetic risk factors. Infection with human immunodeficiency virus (HIV) also predisposes to invasive pneumococcal disease and so the incidence of this disease in young children is expected to rise as increasing numbers of African and Asian children are born with a perinatally acquired HIV infection. Until recently, pneumococcal infections could be treated effectively with penicillin, a cheap and safe antibiotic. However, pneumococci that are resistant to penicillin are becoming prevalent in many countries, necessitating a change to more costly antibiotics which may be beyond the reach of the health services of poor, developing counties. The spread of antibiotic resistance has provided an added stimulus to the development of vaccines that might be able to prevent pneumococcal disease in infants. Recently developed polysaccharide–protein conjugate vaccines show promise and are now undergoing field trials. How deployment of these vaccines will influence the balance between invasive pneumococcal infections and asymptomatic nasopharyngeal carriage of pneumococci is uncertain.

scholarly journals An observational study on pneumococcal and influenza vaccination status of patients with type 2 diabetes mellitus

2018 ◽  
Vol 6 (12) ◽  
pp. 3842
Author(s):  
Rafiq A. Bhat ◽  
Saleem A. Wani ◽  
Rajat Kharbanda ◽  
Sumit Sethi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pneumococcal Disease ◽  
Pneumococcal Vaccination ◽  
Vaccination Rates ◽  
Vaccination Uptake ◽  
Increased Risk ◽  
Patients With Diabetes

Background: India has more than sixty million subjects with diabetes. Diabetes confers an increased risk of developing and dying from infectious diseases with an enhanced susceptibility to morbidity, mortality and hospitalizations due to influenza and pneumococcal disease. The Advisory Committee on Immunization Practices (ACIP) recommends influenza and pneumococcal vaccines for all individuals with diabetes.Methods: Around 249 patients with type 2 diabetes mellitus were enrolled in the study. All patients were asked a detailed history about diabetes, its duration, type of diabetes and the vaccinations for influenza and pneumococcus, who suggested vaccination and the reasons for declining the vaccination if it had been medically advised. Any other co-morbid condition such as hypertension, diabetes mellitus, heart disease, COPD, hypothyroidism and CKD were noted.Results: Vaccination rates for influenza in patients aged 50 or more were higher (7.6% of 172 patients) as compared to those aged <50 years (0% of 77); (p=0.013) whereas pneumococcal vaccination rates were 8.1% as against 1.3% (p=0.036) respectively. In males the vaccination rates for influenza were 4.7% compared to females (5.8%); (p=0.675), whereas for pneumococcus the respective vaccination rates were 6.2% for male and 5.8% for female (p=0.903). Vaccination uptake among male and female were almost same. Patients having chronic kidney disease on dialysis were having highest vaccination rate.Conclusions: The poor vaccination uptake for influenza and pneumococcus in patients with diabetes, calls for intensive efforts aimed at increasing coverage.

scholarly journals Further available immunization option to prevent pneumococcal disease

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 3
Author(s):  
Ivo Vojtek ◽  
Bernard Hoet
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Real Life ◽  
Clinical Aspects ◽  
Pneumococcal Infections ◽  
Additional Information ◽  
Life Data ◽  
Real Life Data

In their recent review, Charles Feldman and Ronald Anderson provide an overview of various clinical aspects of pneumococcal infections. We would like to complete this report by providing some additional information on a widely-used immunization option, which was not originally mentioned in the article. The protein D pneumococcal conjugate vaccine (PHiD-CV) has been pre-approved by WHO and its impact is supported by real-life data from the regions of its use.

scholarly journals Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012–2018

2021 ◽  
Vol 9 ◽  
Author(s):  
Larisa Savrasova ◽  
Angelika Krumina ◽  
Hedija Cupeca ◽  
Indra Zeltina ◽  
Anita Villerusha ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Pneumococcal Infection ◽  
Case Fatality ◽  
Surveillance Data ◽  
Vaccine Serotypes ◽  
Increasing Trend ◽  
Chi2 Test

In 2010 in Latvia, invasive pneumococcal disease (IPD) became a cause for concern and vaccination of infants with four doses of 7–valent pneumococcal conjugate vaccine (PCV7) commenced. In 2012, 10–valent pneumococcal conjugate vaccine (PCV10) (three doses at 2, 4, and 12–15 month of age) vaccination was introduced. We described incidence and serotype distribution of IPD in Latvia and investigated serotypes associated with death from IPD based on surveillance data. Adult vaccination against pneumococcal infection is not included in the national immunization program. Laboratory confirmed IPD cases are passively notified to the Center for Disease Prevention and Control of Latvia (CDPC) by laboratories and clinicians. We calculated incidence by age, sex, case fatality, and trend in serotypes by conducting a retrospective population-based cross-sectional study based on national IPD surveillance data. From 2012 to 2018 466 cases of IPD were reported. The highest notified incidence was in 2015 at 4.4/100,000, which fell to 3.9 in 2018. The highest mean annual IPD incidence was in infants (4.8) and in the elderly (6.0). PCV10 vaccine serotypes were the most prevalent in IPD cases up to 2015 with a decreasing trend from 50% (20/40) in 2012 to 19% (14/74) in 2018 (chi2 test for trend of odds = 0.000). PCV23nonPCV13 vaccine serotypes had an increasing trend and rose from 18% (7/40) to 34% (25/74) (chi2 test for trend of odds = 0.000). Non-Vaccine serotypes had an increasing trend and rose from 13% (5/40) to 27% (20/74) (chi2 test for trend of odds = 0.038). Reported total case fatality was 19% (87/466). The highest, at 36% (20/56), was reported in 2013. After adjusting for age, Streptococcus pneumoniae serotype 3 was associated with death from IPD (adjusted OR 2.3 95%CI 1.25–4.12 p 0.007). Surveillance data indicate evidence of serotype replacement with an increasing trend of serotype 19A and PPV23nonPCV13 and Non-Vaccine serotypes. Serotype 3 and age were associated with fatal IPD outcome. Further studies of S. pneumoniae carriage would be useful in providing more evidence to characterize serotypes' circulation.

scholarly journals Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy

Pathogens ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 76
Author(s):  
Filippo Ansaldi ◽  
Sarah Pugh ◽  
Daniela Amicizia ◽  
Roberto Di Virgilio ◽  
Cecilia Trucchi ◽  
...  
Keyword(s):  
Public Health ◽  
Economic Impact ◽  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Time Horizon ◽  
Pneumococcal Disease ◽  
Cost Effective ◽  
The Elderly ◽  
Sensitivity Analyses

Background: Invasive and non-invasive pneumococcal diseases are significant health and economic burdens, especially in children and the elderly. Italy included the 7-valent (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) in the National Immunization Program in 2007 and 2010, respectively, allowing a dramatic reduction in the burden of pneumococcal disease. In the era of budget constraints, decision-makers may consider switching from the higher-valent, more costly PCV13, to the lower-cost PCV10. This study estimated the potential public health and economic impact of changing vaccine programs from PCV13 to PCV10 in Italy. Methods: A decision-analytic forecasting model estimated the impact of PCV programs. Real-world surveillance data were used to forecast serotype distribution and disease incidence among children and the elderly over a specified 5-year time horizon. Costs and outcomes included estimates of cases and deaths avoided, quality-adjusted life years (QALYs) gained, and total costs from a payer perspective, discounted at an assumed rate of 3.0%, and robustness validated through several scenarios and sensitivity analyses. Results: A switch from PCV13 to PCV10 would increase invasive pneumococcal disease (IPD) cases by 59.3% (4317 cases) over a 5-year horizon, primarily due to serotypes 3 and 19A. Pneumonia increased by 8.3% and acute otitis media (AOM) by 96.1%. Maintaining a PCV13 program would prevent a total incremental 531,435 disease cases (1.02M over a 10-year time horizon) and 641 deaths due to invasive pneumococcal disease (IPD), with €23,642 per QALY gained over 5 years versus PCV10. One-way and probabilistic sensitivity analyses showed that a PCV13-based program remained cost-effective in 99.7% of the simulations in Italy as parameters varied within their plausible range; percent vaccinated had the most impact. Conclusions: Maintaining the PCV13 strategy would provide substantial public health and economic benefits in Italy and is cost-effective. Switching from PCV13 to PCV10 would increase the incidence of pneumococcal disease primarily linked to re-emergence of serotypes 3 and 19A.

scholarly journals Analysis of Invasive Pneumococcal Infections Due to 13-Pneumococcal Conjugate Vaccine Serotypes at 8 US Children’s Hospitals During 2014 to 2016

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S67-S67
Author(s):  
Sheldon L Kaplan ◽  
William J Barson ◽  
Philana Ling Lin ◽  
Jose R Romero ◽  
John S Bradley ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Age At Diagnosis ◽  
Pneumococcal Infections ◽  
Research Support ◽  
Children's Hospitals ◽  
Children’S Hospitals ◽  
The Us ◽  
Research Grant

Abstract Background The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) was licensed in 2010 and is directed against serotypes (ST) 1,3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Details of cases of invasive pneumococcal disease (IPD) due to PCV13 ST since 2010 in the US are sparse. We describe IPD cases due to PCV13 ST seen at 8 US children’s hospitals over years 2014 to 2016 which may aid in understanding why some IPD cases due to these ST have persisted. Methods Children with IPD have been prospectively identified at 8 children’s hospitals in the US since 1993. Data from 2014 through 2016 were analyzed. Demographic, clinical data and number and dates of PCV doses were collected on case report forms and isolates were sent to a central laboratory for serotyping. PCV doses are counted if IPD occurred &gt; 2 weeks after a dose. Results PCV13 ST accounted for 19.7% (27/137), 26.8% (30/112) and 26% (33/127) of IPD cases in 2014, 2015 and 2016, respectively. ST 3, 19A and 19F accounted for 90% of the PCV13 ST IPD cases. &gt;50% of the children had received ≤2 doses of PCV13 prior to IPD. (Table) Of the 30 children with 0 doses of PCV, 15 were of an age at diagnosis for which ≥ 2 doses of PCV was recommended. An underlying condition was noted in 18. For PCV13 ST, the types of IPD were pneumonia (n = 39), mastoiditis (n = 15), bacteremia (n = 15), meningitis (n = 12) and other sites of infection (n = 9). Whereas the numbers of yearly cases were similar for ST3 (12, 10, 13) and ST19A (8, 10, 6), the numbers for 19F increased slightly (3, 8, 10). Conclusion Four to 6 years after PCV13 was introduced, PCV13 ST (especially ST 3, 19A and 19F) accounted for about 25% of IPD in children. For all of the PCV13 ST, over half of these IPD cases occurred in children who had received ≤ 2 doses of the recommended PCV schedule; 25% of cases occurred in children who had not received any doses but were of the age at diagnosis that at least 2 PCV doses should have been received. Additional PCV13 ST IPD cases may be preventable if the PCV13 schedule is followed as recommended. Disclosures S. L. Kaplan, Pfizer: Grant Investigator and Speaker at PCV13 Launch Meeting in China, Research grant and Speaker honorarium; J. S. Bradley, Merck & Co., Inc.: Investigator, Research support

Sign in / Sign up

Export Citation Format

Share Document